)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
T2 Biosystems
T2 Biosystems (TTOO) investor relations material
T2 Biosystems has been delisted
T2 Biosystems Q4 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2024 earnings summary7 Jan, 2025
Executive summary
Achieved record sepsis product revenues in Q4 2024 ($2.3M) and full year 2024 ($8.3M), up 37% and 23% year-over-year, respectively, driven by strong sepsis test sales.
Expanded global installed base with 27 T2Dx Instruments sold in 2024, including 23 internationally and 4 in the U.S.
Entered exclusive U.S. distribution agreement with Cardinal Health for key sepsis detection products.
Advanced product pipeline with FDA 510(k) clearances and progress on new diagnostic panels.
Financial highlights
Q4 2024 product revenue reached $2.3M, a 37% increase year-over-year; full year 2024 product revenue was $8.3M, up 23% year-over-year.
Cash and cash equivalents totaled $1.7M as of December 31, 2024.
Converted $30M of term loan into common stock, reducing debt and quarterly interest payments by approximately 80% over the past year.
Outlook and guidance
Expects exclusive Cardinal Health agreement to drive commercial growth in 2025.
Plans to accelerate product sales, enhance operations, and advance new product pipeline in 2025.
Anticipates FDA 510(k) submission for T2Resistance Panel in Q1 2025.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from T2 Biosystems
- Rapid sepsis diagnostics and new product launches drive strong growth outlook for late 2024.TTOO
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 - Cardinal Health partnership and AI collaboration set stage for accelerated growth and innovation.TTOOStatus Update
- Q3 revenue up 34% year-over-year, but urgent funding is needed to sustain operations.TTOOQ3 2024
- Rapid sepsis diagnostics drive record growth, global expansion, and pipeline advances in 2024.TTOOH.C. Wainwright 26th Annual Global Investment Conference 2024
- Rapid sepsis diagnostics, strong clinical impact, and new partnerships drive growth outlook.TTOOSidoti Micro-Cap Virtual Conference
- Record sepsis test growth, debt cut, but cash shortfall threatens ongoing operations.TTOOQ2 2024
T2 Biosystems
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. The company develops integrated systems for implantable devices and other devices used to administer therapies and monitor outcomes. Its integrated systems provide measurement at the sensor, electronics, and software layers. The company also provides patient adherence monitoring solutions comprising portable medical devices, bio-markers, the Emeter® 2 diabetes management platform, and a new removable stent-based blood glucose meter that captures measurements directly from the body with a minimally invasive procedure called transcutaneous measuring technique (TMT). The company's Transmettor Plus integrates blood glucose data directly into Medtronic's MiniMed® Paradigm insulin pump as well as Dexcom's G4® CGM to improve overall glycemic control. It also offers technology platforms comprising biosensors, electronic circuits, adhesive arrays, and microfluidics for a range of diagnostic applications including potential use in point-of-care (POC) systems. T2 Biosystems is based in Lexington, Massachusetts.